Our findings suggest that CCDC6 expression may be useful as a prognostic biomarker during targeted therapy and immunotherapy, and they provide insights into the molecular mechanisms that differ between patients with HCC and those with CCA. The gene discussed is CCDC6; the disease is hepatocellular carcinoma.